Consolidation radioimmunotherapy of follicular lymphoma: A step towards cure?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1236-1239

  Chatal, Jean François ^a   Kraeber Bodéré, Françoise ^a   Barbet, Jacques ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SALVAGE THERAPY; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, FOLLICULAR; NEOPLASM, RESIDUAL; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45049084047     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0727-z     Document Type: Editorial

References (22)

1. DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Svtsma VM, Mills SL, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 1988;3:96-101.
2. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38.
3. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-76.
4. Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm 2006;21:1-4.
5. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
6. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:629-3.
7. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606-12.
8. Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma. J Clin Oncol 2004;22:560a. (suppl, abstr 6520).
9. Leonard JP, Coleman M, Kostakoglu L, Chadbum A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704.
10. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-49.
11. Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by Y-90 ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2005;23:579. (suppl I; abstr 6577).
12. 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients. Blood 2007;110:198a. (suppl; abstr 643).
13. Jurczak W, Giza A, Zimowska-Curylo D, Hubalewska-Dydejczk A, Sowa-Staszczak A, Knopinska-Posluszny W, et al. 90Y-Zevalin® (90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not eligible for intensive therapy protocols. Blood 2007;110:(suppl; abstr 4497).
14. Van Oers MHJ. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007;92:826-33.
15. Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:1548-55.
16. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44:2000-18.
17. Shimoni A, Nagler A. Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leuk Lymphoma 2007;48:2110-20.
18. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90-5.
19. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70.
20. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.
21. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin oncol 2006;24:1705-11.
22. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, Mcbride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-55.